• Ep 6- Dispelling Myths About Biosimilars

  • Dec 15 2021
  • Duración: 10 m
  • Podcast
Ep 6- Dispelling Myths About Biosimilars Por arte de portada

Ep 6- Dispelling Myths About Biosimilars

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • Biosimilars were first introduced into the US market about six years ago, but getting the all-important “patient buy-in” has been a slow process. Many patients are reluctant to switch to a biosimilar if they’re already happy taking a biologic. But another reason is the proliferation of myths and misinformation about biosimilars, which can be difficult to counteract.

    In this episode, Zoe and Conner talk to a few medical professionals about the most common biosimilar falsehoods, and what can be done to stop their spread.

    Among the highlights in this episode:

    1:58 – The FDA begins cracking down on misinformation

    2:47 – Myth #1: Patients confuse biosimilar drugs with generic drugs

    3:06 – Doctors’ initial concerns about quality control

    3:38 – Hesitancy about ‘transferability’

    4:54 – Myth #2: Biosimilars won’t save money

    5:50 – Myth #3: Biologics are natural monopolies

    Contact Our Hosts:

    Zoe Rothblatt, Patient Advocate and Community Outreach Manager at GHLF. zrothblatt@ghlf.org

    Conner Mertens, Patient Advocate and Community Outreach Manager at GHLF. cmertens@ghlf.org

    We’d love to hear what you think. Send your comments to BreakingDownBiosimilars@GHLF.org

    See omnystudio.com/listener for privacy information.
    Más Menos
Más Menos

Lo que los oyentes dicen sobre Ep 6- Dispelling Myths About Biosimilars

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles